Overview

This trial is active, not recruiting.

Condition papillary thyroid cancer
Treatment 99mtc-mibi spect-ct
Sponsor Chulalongkorn University
Start date March 2010
End date October 2011
Trial size 15 participants
Trial identifier NCT00984191, NapadonChula_01

Summary

The purpose of this trial is to see if the 99mTechnetium-MIBI SPECT-CT can be a tool for preoperative evaluation of cervical node metastasis in papillary thyroid cancer.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Intervention model parallel assignment
Masking open label
Primary purpose diagnostic
Arm
(Experimental)
99mTechnetium-MIBI SPECT-CT positive compare : Scan - Pathologic report
99mtc-mibi spect-ct
99mTc-MIBI SPECT-CT for abnormal cervical lymph node
(Experimental)
99mTc Negative but have neck dissection indication compare : 99mTc - Pathologic report
99mtc-mibi spect-ct
99mTc-MIBI SPECT-CT for abnormal cervical lymph node
(Experimental)
99mTc Negative and No other indication for neck dissection compare : 99mTc - 7. 131I (post-treatment) whole body scan
99mtc-mibi spect-ct
99mTc-MIBI SPECT-CT for abnormal cervical lymph node

Primary Outcomes

Measure
Diagnostic Tool Statistic (PPV , NPV , Sensitivity , Specificity , Accuracy )
time frame: 18 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - papillary thyroid cancer Exclusion Criteria: - pregnancy - Bleeding abnormality - Prior history of head and neck cancer - can not perform 99mTechnetium-MIBI SPECT-CT - can not perform 131I remnant Ablation - Prior any head and neck surgery within 3 months - Prior deep neck infection within 3 months

Additional Information

Official title 99mTechnetium-MIBI SPECT-CT for Pre-operative Evaluation of Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma; A Pilot Study
Principal investigator Napadon Tangjaturonrasme, Otolaryngologist
Trial information was received from ClinicalTrials.gov and was last updated in June 2011.
Information provided to ClinicalTrials.gov by Chulalongkorn University.